Literature DB >> 11991242

Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium.

Ana Pérez-Ruiz1, Ramón Montes, Pilar Carrasco, Eduardo Rocha.   

Abstract

Human endothelial cells synthesize and secrete a variety of molecules involved in fibrinolysis and coagulation. The effects of a low molecular weight heparin, Bemiparin, and unfractionated heparin (UFH) were compared on plasminogen activator inhibitor-1 (PAI-1), tissue-plasminogen activator (t-PA), tissue factor (TF), tissue factor pathway inhibitor (TFPI) release, and PAI-1 gene expression by human umbilical vein endothelial cells (HUVEC). Cell cultures were supplemented with Bemiparin or UFH at 1 or 10 U/mL. Culture media samples were obtained before the addition of the drugs and 2, 6, and 24 hours afterward to measure the antigen levels of TF, TFPI, t-PA, and PAI-1. RNA was obtained to study the endothelial expression of PAI-1 by reverse transcriptase-polymerase chain reaction (RT-PCR). Bemiparin at 1 U/mL resulted in a decreased messenger RNA (mRNA) PAI-1 expression, which remained unaltered when UFH had been added. PAI-1 levels increased after the cultures had been supplemented with either Bemiparin or UFH at both doses. UFH induced an increase in t-PA either at 1 or 10 U/mL. Both doses of UFH, but not Bemiparin, induced an important increase in TF secretion. An increase in the TFPI levels was seen with UFH at 1 U/mL. The decrease in PAI-1 gene expression observed with a therapeutic dose of Bemiparin might confer this drug interesting profibrinolytic properties. The fact that Bemiparin, in contrast with UFH, does not induce an increase in TF could give this drug another positive feature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991242     DOI: 10.1177/107602960200800109

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

Review 1.  Bemiparin: pharmacological profile.

Authors:  Carlos F Sánchez-Ferrer
Journal:  Drugs       Date:  2010-12-14       Impact factor: 9.546

Review 2.  Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.

Authors:  Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates.

Authors:  Ahmed Kouta; Debra Hoppensteadt; Emily Bontekoe; Walter Jeske; Richard Duff; Lee Cera; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.